Search Results
Aug 03, 2026, 08:00 ET Lipocine Appoints Michael J. Grissinger to Board of Directors
proprietary technology platform to develop innovative products with effective oral delivery. Lipocine has drug candidates in development as well as drug candidates for which we are exploring partnerships. Our drug candidates represent enablement of differentiated, patient friendly oral delivery options for favorable
More news about: Lipocine Inc.
Aug 03, 2026, 08:00 ET cAMPfield Strengthens Leadership Team with Key Executive Appointments, Including Graham Heap, MD, PhD as President, R&D, to Advance Prifemilast into Global Phase 2 Development for Inflammatory Bowel Disease
scientific communications, and external engagement. Scott Stirn, DSc joins as Head of Chemistry, Manufacturing, and Controls (CMC) and will lead drug substance and drug product development, manufacturing scale-up, analytical development, and clinical supply of prifemilast.These appointments deepen cAMPfield's
More news about: cAMPfield Therapeutics
Aug 03, 2026, 08:00 ET FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection
minutes from a July 13, 2026 Type C Meeting to discuss ibezapolstat's (IBZ) Phase 3 clinical program, including the potential to submit an NDA (New Drug Application) based on a single Phase 3 trial and a clinical trial design intended to support indications for both treatment and reduction of recurrence
More news about: Acurx Pharmaceuticals, Inc.
Aug 03, 2026, 08:00 ET Triquetra Health Launches BioActive Vitamin B1™--First Complete B1 Activation System with 600mg Research-Matched Dose and Full Cofactor Support
triquetrahealth.com These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
More news about: Triquetra Health LLC
Aug 03, 2026, 07:45 ET Lilly's olomorasib receives U.S. FDA's Breakthrough Therapy designation for the treatment of previously treated KRAS G12C-mutant advanced pancreatic cancer
U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olomorasib as a monotherapy for the treatment of adult patients with advanced
More news about: Eli Lilly and Company
Aug 03, 2026, 07:30 ET Keenova Announces Publication of XIAFLEX® (collagenase clostridium histolyticum) Manuscript in Translational Andrology and Urology
Clinical trialsIn the XIAFLEX clinical trials for Peyronie's disease, the most frequently reported adverse drug reactions (≥25%) and at an incidence greater than placebo included: penile hematoma, penile swelling, and penile pain.Post-marketing
More news about: Keenova Therapeutics
Aug 03, 2026, 07:00 ET Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies
personalized treatment options."The collaboration leverages Roche Diagnostics' expertise in assay development. Roche Diagnostics received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation for the first AI-driven companion diagnostic for NSCLC that uses a TROP2 score to evaluate NSCLC
More news about: Genprex, Inc.
Aug 03, 2026, 07:00 ET Compugen Reports Second Quarter 2026 Results
2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational drug target discovery powered by AI/ML, today reported financial results for the second quarter of 2026 and provided a corporate update. "Q2 2026
More news about: Compugen Ltd.
Aug 03, 2026, 06:55 ET Ascletis Announces Initiation of Global Phase III for Oral Small Molecule GLP-1, ASC30 and Positive Preclinical Data for Its First-in-Class Oral Small Molecule GLP-1/GIP/Amylin Fixed-Dose Combination
proprietary Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD) and Ultra-Long-Acting Platform (ULAP) technologies as well as Peptide Oral Transport ENhancement Technology (POTENT), Ascletis has developed multiple drug candidates in-house, including both small molecules and peptides,
More news about: Ascletis Pharma Inc.
Aug 03, 2026, 06:55 ET 歌禮宣佈其GLP-1口服小分子ASC30啟動全球III期臨床研究，並公佈其同類首創口服小分子GLP-1/GIP/胰澱素固定劑量復方制劑的積極臨床前數據
歌禮製藥有限公司是一家全價值鏈整合型生物技術公司，聚焦有望成為治療代謝疾病同類最佳（best-in-class）和同類首創（first-in-class）藥物的開發和商業化。利用公司專有的基於結構的AI輔助藥物發現（Artificial Intelligence-assisted Structure-Based Drug Discovery，AISBDD）、超長效藥物開發平台（Ultra-Long-Acting Platform，ULAP）技術以及口服多肽遞送增強技術（Peptide Oral Transport ENhancement Technology，POTENT），歌禮已自主研發多款小分子和多肽候選藥
More news about: 歌禮製藥有限公司
Aug 03, 2026, 06:00 ET Varda Announces Biopharma Leader Mikael Dolsten will Join Board as Space-Based Pharmaceutical Manufacturing Accelerates
Scientific Officer and President of Pfizer R&D, where he oversaw the approval of more than 36 medicines and vaccines and advanced more than 150 drug candidates into clinical studies.
More news about: Varda Space Industries Inc.
Aug 03, 2026, 05:49 ET WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance[1], Driven by Greater Success of Multiple Customers' Products and CRDMO Model
AppTec remains steadfast in 'doing the right thing and doing it right.' We will relentlessly enable global innovators and realize our vision that 'every drug can be made and every disease can be treated.'"Sustainability, and Quality ComplianceWuXi AppTec maintained the highest "AAA" MSCI
More news about: WuXi AppTec
Aug 03, 2026, 02:22 ET MPLT Investors Have Opportunity to Join MapLight Therapeutics, Inc. Fraud Investigation with SBS Law
investors. On July 27, 2026, MapLight shares fell more than 50% in premarket trading after its Phase 2 trial reported mixed results for its schizophrenia drug candidate. According to the Company, "The 330/6 mg once-daily dose, which results in lower daily exposure than BID dosing, demonstrated numerical improvement
More news about: Schall, Brown & Schwartz LLP
Aug 03, 2026, 01:00 ET Capricor Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - CAPR
data for Deramiocel. The Company failed to secure the FDA's agreement to this change before it resubmitted a Biologics License Application for the drug. Based on these facts, Capricor's public statements were false and materially misleading throughout the class period.If you are a shareholder
More news about: DJS Law Group LLP
Aug 02, 2026, 21:00 ET GlycoNex Doses First Patient in Phase I Trial of GNX1021, Advancing Its Glycan-Directed ADC into Clinical Development
first patient has been successfully dosed in the First-in-Human (FIH) Phase I clinical trial of GNX1021, the Company's novel glycan-targeting antibody-drug conjugate (ADC), in Japan. The milestone marks GNX1021's transition into clinical development and initiates the generation of the first human data for
More news about: GlycoNex Inc.
Aug 02, 2026, 11:13 ET Mezzion Reports Positive In Vivo Results for Udenafil in ADPKD
scientific rationale for advancing udenafil in ADPKD," said Dong Hyun Park, Chairman and CEO of Mezzion. "As previously announced, the U.S. Food and Drug Administration (FDA) indicated that Mezzion's nonclinical data package, together with its prior clinical and safety experience with udenafil, provides
More news about: Mezzion Pharma Co., Ltd.
Aug 02, 2026, 10:01 ET New Chemotherapy-Free Immunotherapy Combination for Follicular Lymphoma Listed on the PBS
rights to develop and commercialise Minjuvi from Xencor, Inc. In the U.S., Monjuvi® (tafasitamab-cxix) is approved by the U.S. Food and Drug Administration in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).
More news about: Specialised Therapeutics
Aug 02, 2026, 05:30 ET Best Ways to Dispose of Needles at Home Safely (2026): Sharps Assure Recognized by Consumer365
pens, and infusion sets can cause injuries or expose people to bloodborne infections when discarded incorrectly.According to the U.S. Food and Drug Administration, used sharps should be placed in a suitable disposal container immediately after use. Loose needles should never be put in household
More news about: Consumer365.org
Aug 01, 2026, 13:06 ET Now, More Than Ever: Thousands of Cyclists and Volunteers Unite for 2026 Pan-Mass Challenge, Raising Critically Needed Funds for Cancer Research and Care
pancreatic cancer research, Dr. Wolpin serves as the Principal Investigator of a groundbreaking clinical trial examining the experimental gene-targeting drug daraxonrasib, which doubled median survival for participating pancreatic cancer patients.During each annual PMC weekend, more than 10,000 collective
More news about: Pan-Mass Challenge
Aug 01, 2026, 12:27 ET Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action Investigation - IRON
action.What is this about: On February 13, 2026, the U.S. Food and Drug Administration ("FDA") issued a Complete Response Letter ("CRL") to Disc Medicine regarding its bitopertin program. The FDA stated they could not approve Disc Medicine's new drug application ("NDA") as there were uncertainties in the NDA
More news about: THE ROSEN LAW FIRM, P. A.
Jul 31, 2026, 17:34 ET FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
trial evaluating CYWC628 for the treatment of diabetic foot ulcers (DFUs).Completed manufacturing of three batches of the CYWC628 drug product in accordance with FDA's Good Manufacturing Practices (cGMP). Two of these batches have been released and the third batch will be released after
More news about: FibroBiologics, Inc.
Jul 31, 2026, 14:48 ET American Regent, Inc. Animal Health Issues Nationwide Recall of two lots of Adequan® Canine and two lots of Adequan® i.m. due to visible glass fiber material in the product
http://www.FDA.gov/reportanimalae.This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.American Regent, Inc. is committed to the safety of patients who rely on its products and is taking this precautionary action
More news about: American Regent, Inc.
Jul 31, 2026, 12:27 ET In HelloNation, Benefits Expert Carl Stecker Examines Whether Better Benefits Help Employers Attract and Keep Good Workers
to.The impact of benefits on employee retention is described as equally significant. Employees who feel supported through health coverage, prescription drug coverage, and wellness resources tend to report higher job satisfaction. The article explains that satisfaction is one of the strongest predictors of
More news about: HelloNation
Jul 31, 2026, 11:30 ET In HelloNation, Prescription Savings Expert Carl Stecker Outlines How to Lower Prescription Costs Without Insurance
as the first and most accessible option for uninsured patients. A generic drug contains the same active ingredient as its brand-name equivalent and must meet the same safety and effectiveness standards set by the Food and Drug Administration. Prices for generic medications are typically far lower than
More news about: HelloNation
Jul 31, 2026, 11:22 ET CELC Investigation: Kessler Topaz Meltzer & Check, LLP Encourages Celcuity Inc. (NASDAQ: CELC) Investors to Contact the Firm
Celcuity Announces Unexpected Delayed Drug LaunchOn July 14, 2026, Celcuity Inc. issued a press release announcing that it had secured FDA approval for its breast cancer
More news about: Kessler Topaz Meltzer & Check, LLP